can yield significant insights into these complex and dynamic processes through integration of prior biological data. Objective: We sought to develop a multiscale mathematical model of AD pathogenesis that describes the dynamic interplay between the skin barrier, environmental stress, and immune dysregulation and use it to achieve a coherent mechanistic understanding of the onset, progression, and prevention of AD. Methods: We mathematically investigated synergistic effects of known genetic and environmental risk factors on the dynamic onset and progression of the AD phenotype, from a mostly asymptomatic mild phenotype to a severe treatment-resistant form. Results: Our model analysis identified a ''double switch,'' with 2 concatenated bistable switches, as a key network motif that dictates AD pathogenesis: the first switch is responsible for the reversible onset of inflammation, and the second switch is triggered by long-lasting or frequent activation of the first switch, causing irreversible onset of systemic T H 2 sensitization and worsening of AD symptoms. Conclusions: Our mathematical analysis of the bistable switch predicts that genetic risk factors decrease the threshold of environmental stressors to trigger systemic T H 2 sensitization. This analysis predicts and explains 4 common clinical AD phenotypes from a mild and reversible phenotype through to severe and recalcitrant disease and provides a mechanistic explanation for clinically demonstrated preventive effects of emollient treatments against development of AD. (J Allergy Clin Immunol 2017;139:1861-72.)
Key words: Atopic dermatitis, mathematical models, double switch, disease progression, disease phenotypes, preventive treatment Atopic dermatitis (AD) is a common chronic skin disease characterized by persistent skin inflammation and a defective skin barrier prone to infections. 1 Although AD affects up to 25% of children worldwide, 2 with a continuous increase in the number of patients and treatment costs, 3 clear guidance and consensus for effective treatment strategies for the prevention and induction of remission are yet to be fully established. 4 The scientific basis for recent clinical recommendations of ''proactive therapy'' is largely based on clinical trial data with limited duration and scope 5 and waits to be further strengthened by a better understanding of the pathogenic mechanisms of AD. However, a systems-level understanding of AD pathogenesis might lie beyond the ethical and practical reach permitted by clinical and experimental studies and could be supported by a systematic and extensive investigation of the disease dynamics by using mathematical models. 6, 7 Previous studies have identified genetic and environmental risk factors for AD onset, including defects in skin barrier function (the filaggrin gene encoding profilaggrin [8] [9] [10] [11] and 30 other putative loci for skin barrier function) and in the immune system, including innate and adaptive immunity. [12] [13] [14] In addition, microbiome composition has been shown to play a critical role. 15, 16 Each of these risk factors perturbs the system of strongly intertwined regulatory interactions between the keratinocytes (which, along with the extracellular lipids, provide barrier function and also initiate many innate immune responses in the epidermis) and mediators of the adaptive immunity, such as dendritic cells (DCs) and T cells. Perturbations triggered at one part of the system can propagate to another part through interactions, causing synergistic effects of risk factors and a gradual aggravation of the AD phenotype from a mostly asymptomatic mild phenotype at its early stage 17 to a severe treatment-resistant form. 18 Understanding of this dynamic pathogenesis thus requires elucidation of the synergistic effects of multiple risk factors on AD pathogenesis (eg, mutations in skin barrier components accompanied by environmental insults) and the dynamic interplay between the skin barrier, immunity, and the environment, as suggested by several clinical 14, 19 and animal or in vitro experimental [20] [21] [22] [23] studies. In this study we develop a mathematical in silico model of AD pathogenesis that describes the complex and dynamic interplay between skin barrier function, immune responses, and environmental stressors based on clinical and experimental data and our previous model of the early stage of AD. 24 Through systematic and mathematical investigation of the synergistic effects of risk factors on dynamic progression of AD pathogenesis, we tested the hypothesis that genetic risk factors predispose patients to AD progression and decrease the threshold for environmental stressors to drive severe AD. 25 We uncover mechanisms underlying AD onset and progression, explore effective treatment strategies to prevent progression of AD, and answer 3 basic questions about the onset, progression, and prevention of AD: (1) Why do some patients with genetic AD risk factors appear initially asymptomatic but then develop clinically severe AD? (2) Why do some patients progress to severe AD, whereas others maintain mild AD? (3) What are the underlying mechanisms behind effective prevention of AD development by emollients in neonates, as demonstrated in recent clinical trials? 26, 27 
METHODS

Model description
The proposed model of AD pathogenesis is described by a hybrid system as follows:
for the dynamics of the 3 variables P(t), B(t), and D(t), denoting the infiltrated pathogen load (in milligrams per milliliter), the strength of barrier integrity (relative to the maximum strength), and the concentration of DCs in the lymph node (cells per milliliter), respectively. The dynamics of P(t), B(t), and D(t) depend on the dynamics of the 3 additional variables R(t), G(t), and K(t), denoting the levels of activated immune receptors, Gata3 transcription (relative to the maximum transcription level), and active kallikreins, respectively. The infiltrated pathogen load (P) increases by the penetration of environmental stress load (P env ) through the barrier (B). P is eradicated by innate immune responses triggered by inflammation (R) and is also naturally degraded. The barrier function (B) is determined by the balance between its production and degradation. Barrier production is described by a phenomenological representation of its capacity to self-restore nominal barrier function after its disruption and is compromised by innate immune responses triggered by inflammation (R) and cytokines produced by differentiated T H 2 cells, levels of which increase according to G. The degradation of the barrier occurs as a result of desquamation mediated by active kallikreins (K). The concentration of DCs (D) increases while inflammation (R) persists but DCs degrade naturally. Equation 1 uses simple mathematical terms based on the law of mass action with zero-order production and first-order degradation terms, except for the barrier production term, k x (1 2 x (t)), which represents the phenomenological recovery of skin barrier in response to disruption. 28 The inhibitory rates are described in the form of 1/ (1 1 x) .
The dynamics of R(t), G(t), and K(t) is described by a perfect switch as follows:
, respectively. The minimal stress load that can trigger systemic T H 2 sensitization were numerically determined by evaluating whether the D(t) surpasses the threshold (D 1 ). The minimal treatment times to achieve remission were numerically determined by evaluating the fold-decrease of P env with which the state (P(t), B(t)) enters the healthy basin of attraction. The 95% recovery times were numerically obtained by t 95% 2t min , where B(t 95% ) 5 0.95 and B(t min ) is the minimum barrier integrity achieved after a transient AD flare. All the boxplots show the minimum, first quartile, median, third quartile, and maximum values.
Epidermis-specific signal transducer and activator of transcription 3 knockout mice
We developed keratinocyte-specific signal transducer and activator of transcription 3 (Stat3) knockout (Stat3 f/f ) mice with the B6X129 mixed background. 37 All mice used in this study were maintained under pathogen-free conditions. Animal care was conducted in accordance with guidelines of the RIKEN Yokohama Institute.
Development of AD phenotypes in epidermis-specific Stat3 knockout mice Expression levels of 11 nuclear factor kB (NF-kB) target genes (Bcl2, Ddx26b, Gadd45b, Icam1, Icam2, Icam4, Icam5, Il1b, Tnf, Traf1, Traf2, and Vcam1) selected from the Kyoto Encyclopedia of Genes and Genomes database (http://www.genome.jp/kegg-bin/show_pathway?ko040641K02580) were quantified from sorted ear samples of 2-, 5-, 8-, and 10-week-old Stat3 f/f mice. By using total RNA isolated with TRIzol, cDNAs were synthesized with the NEBNext Ultra RNA Library Prep Kit for Illumina (New England Biolabs, Ipswich, Mass), according to the manufacturer's instructions. Comprehensive expression analysis was performed by using the mRNA sequence (single-ended 50-bp reads) with the HiSeq 3000 system (Illumina, San Diego, Calif; GEO accession no. GSE86071). Read alignment (mm9) was performed with TopHat2, version 2.0.8, and the expression level was determined with Cufflinks, version 2.1.1, with default settings. We calculated mean expression levels of the NF-kB target genes over the 2 mice per cohort (asymptomatic and AD phenotype) and normalized them by using wild-type (WT) dynamics.
Severity of the AD symptoms was assessed in 11 mice at 51 time points by examining the areas of the skin lesion: no lesions (score 0), periocular lesions (score 1/5), lesions on a half side of the face (score 2/5), on a complete side of the face (score 3/5), on the whole face (score 4/5), or on the whole face and ears (score 5/5). The time of systemic sensitization (t 5 0) corresponds to the time when the IgE levels increase to 10% of the maximal IgE level measured for each mouse.
RESULTS
Model overview
Our proposed mathematical model of AD pathogenesis (Fig  1, A and B) is a systems-level representation of the prominent interactions between environmental stressors, skin barrier integrity, and immune responses that were identified based on empiric evidence from numerous clinical 11, 20, [38] [39] [40] and experimental in vivo 22, [41] [42] [43] [44] [45] or in vitro [46] [47] [48] studies. The model is described by a hybrid system of 3 ordinary differential equations (Equation 1) and includes a double-switch motif with 2 concatenated bistable switches (Equations 2, 3), as detailed below. The first switch is responsible for onset of AD flares, and the second switch is responsible for progression to severe AD. The nominal values of the 21 model parameters were identified from the literature (Table I ). This mathematical model includes only the major cellular and biochemical regulators required to describe a global regulatory structure and mechanisms underlying the onset, progression, and prevention of AD rather than explicitly incorporating the fine details of the complex molecular and cellular processes that control epidermal function.
Our model results are validated by clinical and experimental data derived from mouse models with perturbations in either skin barrier function, immune responses, or environmental stressors, the interplay of which is investigated in our model: mouse models with barrier deficiency (flaky tail [ft] mice 21, 22 with the double mutation involving the filaggrin gene (Flg) and Tmem79, which encodes lamellar granules, 49 54, 55 A first switch for onset of AD flares
The first part of the model (processes a-e in Fig 1, A and B , described below) elucidates the mechanisms of how the activity of the first switch (switch-like activation of innate immune receptors) is regulated and leads to AD flares. Healthy barrier integrity protects the body from environmental stressors (process a) and is maintained by a combination of regulated processing of filaggrin 22 and lipid contents, which constitute lipid envelopes of corneocytes. When barrier integrity is compromised by, for example, excessive skin desquamation through active kallikreins, 41 environmental stressors, including pathogens (eg, Staphylococcus aureus), 38 infiltrate the barrier and stress the viable epidermis. They are recognized by innate immune receptors, such as Toll-like receptors (TLRs), which recognize danger-associated molecular patterns and pathogen-associated molecular patterns. 29, 47 Activation of the innate immune receptors triggers innate immune responses to eradicate the infiltrated pathogens through release of antimicrobial peptides (process c), 29 further activates kallikreins (process d), 47 interferes with the de novo production of skin barrier lipids (process e), 42 and triggers inflammation, 43 resulting in AD flares with increased levels of IL-33, 56 thymic stromal lymphopoietin, 44 and other alarmin cytokines. 57 Activation of the innate immune receptors is modelled by a reversible bistable switch 32 between the off and on states (R 5 R off and R on ) with the activation (P 1 ) and inactivation (P 2 ) thresholds for the amount of environmental stressors, such as pathogen load, that are recognized by the innate immune receptors (Fig 1, C , R-switch). When the R-switch is on, clinical symptoms of AD flares appear as increased inflammation accompanied by decreased barrier integrity. Our model demonstrates that activation of the innate immune receptors and the subsequent onset and resolution of AD flares is mainly regulated by a combination of negative and positive feedbacks through innate immune responses and barrier integrity (Fig 1, B) . The relative strengths of the feedbacks can be associated with the 2 most prominent genetic risk factors of AD: mutations in the FLG gene, 8, 9 which results in a higher skin barrier permeability, 23 and a dysregulated expression of innate immune system components, 12 including regulators of antimicrobial peptide expression (eg, TLRs, 58 nucleotide-binding oligomerization domains, 13 and NF-kB 59 ), leading to dysfunctional immune responses and a diminished capacity to eradicate the infiltrated pathogens.
Synergetic effects of genetic risk factors and environmental triggers on dynamic phenotypes for AD flares
We investigated the effects of these 2 genetic risk factors in our model by titrating the model parameters that quantify skin barrier permeability (k P ) and the capacity to eradicate infiltrated pathogens (a I ) in Equation 1. These analyses correspond to examining carriers of different variations of the genetic risk factors and observing how AD can be developed and proceeded in each cohort as a result of the synergistic effects of environmental stressors and the 2 genetic risk factors. Our model analysis revealed the following 4 qualitatively different dynamic phenotypes (Fig 2, A and B) in response to environmental stressors (eg, pathogenic challenges).
When these intrinsic genetic defects do not exist, a quick recovery of the system to the healthy steady state, with homeostatic barrier integrity and no AD flares (R 5 R off ), is achieved after a transient decrease in the barrier integrity and transient AD flares (recovery dynamic phenotype); simultaneous existence of these 2 genetic risk factors results in convergence of the system to the unhealthy steady state, corresponding to a chronically decreased barrier integrity and persistent AD flares (R 5 R on ), which potentially leads to chronic tissue damages (chronic damage dynamic phenotype); genetic defects leading to dysregulated immune responses result in bistability, where wither the healthy or unhealthy steady state is achieved (bistability dynamic phenotype); and genetic defects leading to high skin barrier permeability result in persistent oscillatory dynamics caused by the switching of R between R on and R off (oscillation dynamic phenotype).
The steady state barrier integrity for the oscillation dynamic phenotype is computationally predicted to be indistinguishable from that of the healthy steady state (Fig 2, C) , with a slightly lower mean but increased variability. These long-term dynamic behaviors are concordant with a slightly lower but more variable skin barrier integrity observed in Flg 2/223 and ft mice 21, 22 compared with that seen in WT mice. Our model analysis further predicts a gradual decrease in steady state barrier integrity for increased barrier permeability (k P ), corresponding to the dosedependent effects of filaggrin deficiency on the severity of AD symptoms (Fig 2, D) .
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The bistability dynamic phenotype might also be asymptomatic (or subclinical) if it converges toward the healthy steady state. However, our model analysis demonstrates that the healthy steady state of the bistability dynamic phenotype is distinguishable from that of the recovery dynamic phenotype based on the much longer time for recovery to regain the same healthy steady state from transient barrier damage (Fig 2, E) because of the existence of the second stable (unhealthy) steady state. This model prediction is consistent with the slower skin barrier recovery after tape stripping observed in nonlesional skin of patients with AD compared with healthy subjects 60 and in inflamed compared with noninflamed human skin. 61 The boundaries of the basins of attraction for the bistability dynamic phenotype are computationally obtained by finding the points of tangency between the switching thresholds for the reversible R-switch, P 1 and P
2
, and the (P(t), B(t))-trajectories on the phase plane (Fig 2, F) . The system moves from the healthy to the unhealthy steady state if external inputs (eg, environmental aggressors) push the system into the unhealthy basin of attraction. This worsening of the state was observed in ft mice, [21] [22] [23] as well as in Stat3 knockout mice, which demonstrated AD symptoms only after challenged with haptens or LPS, an activating ligand of the innate immune receptor TLR4 (see Fig E1 in this article' s Online Repository at www.jacionline.org). 62 Likewise, the system can move back to the healthy from the unhealthy steady state if external inputs (eg, treatments) bring the system back to the healthy basin of attraction, achieving remission. Once the remission is induced, maintenance therapy to keep the system in the healthy basin of attraction might achieve control of AD symptoms. 63 This potential switching between the healthy and unhealthy steady states by environmental aggressors or treatments is a distinguished feature of the bistability dynamic phenotype and is not observable in the recovery and chronic damage dynamic phenotypes.
A second switch for progression of AD
The second part of the model (processes f-h in Fig 1, A and B , as described below) includes the main biochemical and cellular players for the allergy-mediating (T H 2) adaptive immune responses triggered by AD flares and is a systems-level synthesis of several lines of empiric evidence from clinical and experimental studies. Using this model, we elucidated mechanisms behind the progression of AD to establish systemic T H 2 sensitization (including increased levels of IgE, a marker of a T H 2-skewed AD phenotype) and systematically investigated how the duration and frequency of AD flares affect the onset of systemic inflammation, including allergic inflammation.
Activation of innate immune receptors causes AD flares with increased levels of cytokines, including thymic stromal lymphopoietin 44 ; alarmins, such as IL-33 56 ; and others, 57 which together contribute to activation of DCs in the epidermis. 45 These activated DCs migrate to lymph nodes (process f), where they increase the IL-4 levels 45 and induce expression of Gata3 (process g), 40 the master transcriptional regulator that controls the irreversible differentiation of naive T cells into T H 2 cells. 45, 48 Differentiated T H 2 cells then migrate back to the epidermis, where they contribute to establish an allergic and proinflammatory microenvironment 39 and release cytokines that downregulate the expression of several epidermal terminal differentiation markers, including filaggrin (process h), 20 thereby further compromising barrier integrity. 11 Compromised barrier integrity results in persistent inflammation, even in the absence of additional environmental stressors.
The transcription level of Gata3 is modelled by an irreversible switch (Fig 1, C, G-switch) 
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: the transcription remains off (G 5 G off ) until sufficient numbers of DCs accumulate in the lymph nodes to reach the activation threshold (D 1 ), with which transcription initiates (G 5 G on ) and persists, even if the DCs disappear (D 5 0). We assume that Gata3-mediated polarization of T cells to T H 2 cells is a hallmark of systemic T H 2 sensitization and that the progression of AD from a mild to more severe phenotype is mediated by this irreversible G-switch. Accordingly, our model of AD pathogenesis suggests that systemic T H 2 sensitization is established if AD flares persist long enough so that D(t) accumulates during the AD flares (R 5 R on ) and reaches D 1 to turn on the G-switch (Fig 3, A,  right) . AD flares that do not persist long enough do not turn on the G-switch because D(t) stays lower than D 1 (Fig 3, A, center) . Our model analysis predicts that a flare time (t on ) of longer than 2.02 days turns on the G-switch (Fig 3, B, see Equation E5 in this article's Online Repository at www.jacionline.org), which is consistent with experimental observations that the peak of Gata3 expression is reached in approximately 2 days after in vitro stimulation of T H 2 cell differentiation. 48 Systemic T H 2 sensitization is spontaneously established in the chronic damage dynamic phenotype because of persistent AD flares and subsequent continuous accumulation of DCs to surpass D
1
, turning on the G-switch.
Periodic AD flares, as in the oscillation dynamic phenotype, are also predicted to turn on the G-switch if the relaxation time (t off ) between AD flares (when R 5 R off ) is too short to prevent a gradual accumulation of DCs that eventually surpass the threshold D 1 (Fig 3, C, right) . The minimum relaxation time above which the G-switch stays off is analytically obtained as a function of the flare time (t on ; white line in Fig 3, D, obtained by using Equation E6 in this article's Online Repository at www.jacionline.org). For example, the R-spikes with a t on of 1 day turns on the G-switch if t off is shorter than 0.93 days (Fig 3, D, red circle) . Our model simulation for R-spikes with a t on of 1 day and t off of 0.9 days predicts turning on of the G-switch within 10 days, which is consistent with several features of AD skin, including T H 2 cell infiltration, as observed in mice after repeated application of oxazolone once every other day over 10 days. 55 
Four AD phenotypes classified by a double switch
Taken together, our model of AD pathogenesis is characterized by a double switch with 2 concatenated bistable switches (R-and G-switches), the status of which represents 4 AD phenotypes of A, The R-switch distinguishes between asymptomatic (R 5 R off ) and symptomatic (R 5 R on ), and the G-switch distinguishes between non-systemic (G 5 G off ) and systemic (G 5 G on ) phenotypes. B-D, Systemic phenotypes demonstrate severe AD symptoms compared with non-systemic counterparts, as computationally predicted by a longer 95% recovery time (Fig  4, B) , longer treatment time required for remission (Fig 4, C) , and lower barrier integrity (Fig 4, D) . different severity (Fig 4, A) . The state of the R-switch determines whether the phenotype is asymptomatic (R 5 R off ) or symptomatic (AD flare, R 5 R on ), and the state of the G-switch determines whether it is systemic (G 5 G on ) or non-systemic (G 5 G off ).
D(t) D(t) R(t) R(t) D(t) D(t) R(t)
For the symptomatic case, in which the R-switch is constantly on and AD flares persist, as in the chronic damage or bistability (unhealthy) dynamic phenotype, the non-systemic symptomatic (R on , G off ) state appears only transiently as it inevitably progresses, after a flare time of t on 5 2.02 days (Fig 3, B) , to the (R on , G on ) state corresponding to the systemic symptomatic phenotype, the most severe AD phenotype with an impaired barrier integrity, systemic inflammation, and infection.
The asymptomatic case, in which the R-switch turns off after a transient AD flare as in the recovery or bistability (healthy) dynamic phenotype, corresponds to either non-systemic asymptomatic (healthy) phenotype in the (R off , G off ) state or systemic asymptomatic phenotype in the (R off , G on ) state with subclinical inflammation caused by T H 2-related cytokines. The systemic phenotype demonstrates more severe AD symptoms compared with its non-systemic counterpart, which are computationally characterized by a longer 95% recovery time (Fig 4, B) . This was suggested by experiments in both WT and Flg 2/2 mice, which recovered from hapten challenge if unsensitized (non-systemic) but did not recover within 2 days if sensitized (systemic). The more severe symptoms are also computationally reflected by a longer treatment time required for remission (Figs 2, F, and 4, C) to drive the system from the unhealthy steady state to the healthy basin of attraction for the systemic than non-systemic phenotype because of enlargement of the unhealthy basin of attraction. This prediction is in agreement with the clinical observation that a much higher treatment effort is required to relieve AD symptoms during the chronic phase of AD, which is characterized by high IgE levels (systemic). 17 The more severe symptoms for the systemic compared with the non-systemic phenotype are also computationally predicted for the case in which R is switching between R off and R on , as in the oscillation dynamic phenotype, by a decrease in the mean and an increase in the variance of the steady state of the barrier integrity (Fig 4, D) . This prediction is consistent with the increase in the mean and variance of the transepidermal water loss (an indicator of barrier defects) measured in ft mice after induction of systemic T H 2 sensitization. 21 
Genetic risk factors predispose to systemic T H 2 sensitization
Here we use our mathematical model of AD pathogenesis to investigate the synergistic effects of environmental and genetic risk factors on AD progression. Specifically, we calculate the minimum stress load (the strength of the environmental stressors [P env ]) that can turn on the G-switch by means of its continuous challenge through an AD flare of a single pulse (Fig 5, A, left) or of transient oscillation (Fig 5, A, right) for different dynamic phenotypes caused by synergetic effects of the genetic risk factors (Fig 2, A and B) . Turning on the G-switch (systemic T H 2 sensitization) might appear as a dramatic increase in the severity of AD symptoms, as observed in ft and Flg 2/2 mice on ovalbumin (OVA) challenge. 21, 23 The minimum stress load was experimentally evaluated in the dose response in WT mice, in which a systemic AD phenotype was developed through challenges with high (10%) but not lower (< _ 2%) concentrations of S aureus in culture supernatants 54 and by 10 repeated, but not single, oxazolone challenges. 55 Our model simulations predict that the minimum stress load is significantly lower for the bistability or oscillation dynamic phenotypes that arise in the context of genetic risk factors compared with the recovery dynamic phenotype, which is mainly observed when the intrinsic genetic defects do not exist (Fig 5, B) . This model prediction suggests that genetic risk factors make the patients susceptible to smaller environmental stressors in developing systemic T H 2 sensitization and is concordant with the experimental observation 22 of a low concentration (0.02%) of oxazolone-induced allergic contact dermatitis in ft mice but not WT mice and a higher concentration (0.5%) of oxazoloneinduced allergic contact dermatitis also in WT mice.
Our predicted increase in the susceptibility to environmental stressors might explain the spontaneous appearance of AD symptoms in some, but not all, carriers of genetic risk factors for AD, as demonstrated in FLG 2/2 patient cohorts. 8 Carriers of the genetic risk factors who initially appear asymptomatic (as in the bistability or oscillation dynamic phenotypes; Fig 2, C) can demonstrate a sudden and sharp worsening of AD symptoms when they experience systemic T H 2 sensitization, even with naturally occurring (small) fluctuations in the environment (Fig 5, B) . This observation also implies a possible mechanism behind the dose-dependent effects of filaggrin deficiency on AD symptoms 9 because the G-switch is turned on by a smaller environmental load for stronger filaggrin deficiency (Fig 5, C) .
To test the model-predicted outcome that small and naturally occurring environmental fluctuations can trigger a sudden and sharp worsening of AD symptoms through systemic T H 2 sensitization in carriers of genetic risk factors, we evaluated the temporal changes in AD symptoms for Stat3 knockout mice in the natural environment with small environmental stressors. Half of the mice had an AD phenotype after 30 weeks, whereas the others remained asymptomatic. Mice that demonstrated an AD phenotype exhibited a much higher expression of the NF-kB target genes (a marker of ubiquitous environmental triggers; Fig 5, D) , 62 suggesting that naturally occurring environmental triggers contributed to the observed development of the AD phenotype. Together with the observations in Stat3 knockout mice that a long-lasting exposure to OVA (environmental stressor) triggered a sharp increase in IgE levels (see Fig E2 in this article's Online Repository at www.jacionline.org) and that AD symptoms sharply increased after allergic systemic T H 2 sensitization (increase of IgE; Fig 5, E) , these experimental results suggest that naturally occurring fluctuations in environmental stressors can trigger systemic T H 2 sensitization in mice with a genetically defective background and worsen their AD symptoms, which is consistent with the model-predicted outcome.
Prevention of AD symptoms by emollient treatments
We further derived the minimum stress load that can turn on the G-switch in the presence of continuous application of emollients computationally. The model predictions confirm that emollient treatments, which strengthen barrier integrity and resistance, 64 reduce the susceptibility to environmental stressors in developing systemic T H 2 sensitization in all asymptomatic patient cohorts considered, as demonstrated by a more than 2-fold increase in the minimum stress load required to turn on the G-switch (Fig 6) . These computational results suggest that topical applications of emollients can counteract the effects of the 2 genetic risk factors investigated in this article (weak barrier integrity and dysregulated immune responses) that asymptomatically increase the susceptibility to environmental stressors and effectively decrease the propensity to develop systemic T H 2 sensitization in response to naturally occurring fluctuations in the environment. B and C, Minimum stress load decreases with genetic risk factors (Fig 5, B) in a dose-dependent manner (Fig  5, C) . D and E, Stat3 knockout mice with AD symptoms had higher NF-kB activity (Fig 5, D) , and the severity of the symptoms increased sharply after T H 2 sensitization (Fig 5, E) .
Ratio of minimal stress load Importantly, our model analysis suggests preventive effects of emollients against the progression of AD through a dynamic interplay between barrier integrity and immune reactions for diverse patient cohorts with different genetic risk factors and not only for those with weak barrier integrity. This prediction is concordant with the results of clinical trials that demonstrated the effective prevention of AD in newborns both with and without filaggrin mutations 26, 27 and recently observed preventive effects of emollients in AD mouse models with weak immune responses caused by Jak1 hyperactivation, in which the incidence of AD symptoms was dramatically reduced by regular application of petrolatum on the skin. 65 
DISCUSSION
This article proposes the first mathematical model of AD pathogenesis that reproduces gradual progression from a mostly asymptomatic mild phenotype at its early stage to a severe treatment-resistant form. Our model is a mechanistic representation of the main feedback control structure that regulates the dynamics of AD flare through a relative strength of barrier function and immune responses, corresponding to positive and negative regulation (Fig 1) .
We computationally demonstrated that the strengths of the 2 well-known risk factors, dysregulated immune responses and high skin barrier permeability, determine the dynamic phenotypes of AD flare by the R-switch and that patients with either of the genetic risk factors might appear asymptomatic initially (Fig 2) . Long-lasting or frequent AD flares trigger the activation of the G-switch, which underlies the onset of systemic T H 2 sensitization (Fig 3) , a hallmark event for progression from mild to clinically severe AD (Fig 4) . Our model simulations suggested that the genetic risk factors predispose the carriers to develop a severe AD phenotype, even in response to naturally occurring fluctuations in environmental stressors (Fig 5) . These susceptible patient cohorts could benefit from preventive emollient treatments, which increase the threshold stress load that drives systemic T H 2 sensitization (Fig 6) .
Our model analysis identified a double switch as a key regulatory motif that determines AD phenotypes of different severity (Fig 4) . The first switch (R-switch) is responsible for the onset of reversible AD flare, and frequent or long-lasting AD flares can trigger the second switch (G-switch), leading to irreversible progression to severe AD through systemic T H 2 sensitization (Fig 7) . Description of the AD phenotypes by the status of the R-and G-switches in our model allows us to uncover and quantitatively investigate the dynamic mechanisms behind worsening or improvement of AD symptoms, which are often evaluated clinically by using an AD score (SCORAD) associated with increased IgE and proinflammatory cytokine levels. 66 The synergetic effects of environmental and genetic risk factors of AD progression determine the dynamics of the R-and Gswitches, which govern a dramatic worsening of AD symptoms through the onset of systemic T H 2 sensitization (G-switch on) and could be a target for effective treatment to prevent progression to a severe form of AD.
Our model simulations reproduced several sets of experimental and clinical results, providing plausible mechanistic, quantitative, and coherent explanations for dynamic mechanisms behind the onset, progression, and prevention of AD. This experimentally validated, quantitative, systems-level mathematical framework can be used to uncover possible early biomarkers and investigate new and better treatment options to reverse and control AD symptoms and prevent progression from mild to clinically severe forms of AD. For example, application of predictive control 67 to our model will allow us to computationally design optimal treatment regimens, with minimal treatment times and strengths for effective proactive treatments, 5, 63 while reducing the risk of the side effects, such as skin atrophy and barrier damage. 68, 69 Our model could also be used to investigate early warning signals 70 to identify asymptomatic but high-risk patient cohorts by their characteristic dynamics in the barrier integrity, such as higher variability (Fig 2, C) or a slower recovery (Fig 2, E) and identify who might benefit from early treatments that prevent an incipient disease development. Another promising future research includes application of machine learning methods 71 to a large set of clinical data with multiple variables to predict the likelihood of the onset, progression, and prevention of AD. It would also be worth evaluating the stochastic effects of the genetic variants when such data become available. Consolidating effective treatment strategies for AD will potentially reduce the social and economic burden of this disease by decreasing clinical symptoms and undesired side effects of the treatments that are associated with the advanced stage of AD. The proposed ''double-switch'' motif provided a coherent explanation of underlying mechanisms behind the dynamic onset, progression, and prevention of AD. The same motif can be found and reveals similar mechanisms underlying the onset, progression, and prevention of other multistage and multifactorial diseases, such as cancers, diabetes, and cardiovascular disease, which are caused by a complex interplay between genetic and environmental factors.
METHODS LPS challenges and histologic evaluation of epidermis-specific Stat3 knockout mice
We backcrossed the keratinocyte-specific Stat3 knockout (Stat3 f/f ) mice on a B6X129 mixed background with a B6 background. We applied 3 intradermal injections with an interval of a week of sterile PBS with 0.1% dimethyl sulfoxide, with and without LPS (10 mg), to the ears of asymptomatic keratinocyte-specific Stat3 f/f mice with a B6 background (8-9 weeks). Two days after the last injection, ears were fixed with paraformaldehyde (4%) and frozen in OCT compound (Sakura Finetek Japan, Tokyo, Japan). Fivemicrometer sections were taken with a cryostat (Leica, Wetzlar, Germany) and fixed onto slide glasses. After retrieval with Target Retrieval Solution (Agilent Technologies, Santa Clara, Calif) and permeabilization (0.1% Trironx-100), the sections were stained with hematoxylin and eosin.
Minimum flare time and minimum relaxation time to trigger systemic T H 2 sensitization 
where the integral is defined over each time segment, on which R(t) is continuously defined, either by R(t) 5 R on for the duration of a flare time (t on ) or by R(t) 5 R off 5 0 for the duration of a relaxation time (t off ). Note that the steadystate value (D ss ) of D(t) while R(t) 5 R on is obtained by D ss 5
kDC Ron dD . The period of the R-spike is denoted by T 5 t on 1 t off .
To determine the dynamics of D(t), we derive D(t k ) and D(T k ) (k 5 1,2,.), where t k and T k denote the time when the k-th spike of R(t) 5 R on starts and the time when the k-th spike ends, respectively. We define t 1 5 0 and D(t 1 ) 5 0. D(t) decreases during T k < _ t < _ t k11 when R(t) 5 R off 5 0 and reaches Dðt k11 Þ 5 e 2dDtoff DðT k Þ, whereas it increases during t k < _ t < _ T k with R(t) 5 R on and achieves Therefore D(T k ) is described as
which converges to
The minimum flare time, t Ã on , for a single pulse of R(t) 5 R on to trigger systemic T H 2 sensitization is analytically obtained from the corresponding solution
The minimum relaxation time, t Ã off , for a periodic R-spike with a fixed t on to trigger systemic T H 2 sensitization is analytically obtained by solving OVA patch challenges and measurement of IgE levels in Stat3 knockout mice
We applied an OVA-soaked patch (1 mg/mL in 100 mL) to the shaved back skin of the 8-to 9-week-old mice (3 WT and 4 epidermis-specific Stat3 knockout mice) 4 times at a week interval between individual applications. We measured the level of OVA-specific IgE titer in the serum by using a sandwich ELISA a week after the last OVA challenge. Briefly, serum was applied on the plastic plate coated with captured antibody for IgE. After washing, the plate was probed with the biotinylated specific OVA antibody for the cytokines and horseradish peroxidase-conjugated streptavidin (Zymed, San Francisco, Calif) and developed with 2,29-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid; Kirkegaard & Perry Laboratories, Gaithersburg, Md). The 405-nm absorbance was measured by using a spectrophotometer (Bio-Rad Laboratories, Hercules, Calif). 
